Treatment Details – 18.0 months
|Patients: This Phase II study involved 22 patients with malignant pleural mesothelioma.|
Treatment: The treatment consisted of the intrapleural administration of interleukin-2. (Interleukin-2 is a cytokine or immune system messenger which encourages the proliferation of CD4 cells.)
Toxicity: Grade 3 toxicities included cardiovascular, weight gain, sepsis, and cutaneous.
Results: The overall median survival time was 18 months.